Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
Conclusion NAMI-A administered in combination with gemcitabine is only moderately tolerated and less active in NSCLC patients after first line treatment than gemcitabine alone.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Constipation | Drugs & Pharmacology | Investigational New Drugs | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology | Urology & Nephrology